VeraDermics Inc (MANE)

NYSEHealth CareBiotechnologySnapshot 2026-10-15

$108.82-5.43%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge VeraDermics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Complete capital raise via public offering	A primary condition in VeraDermics Inc's published investment case. The stated target is Raise at least 3,843,790 shares at $100 per share.	Intact	failure to raise capital via public offering as planned	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 quarters, 2026-Q1 and 2026-Q2. The company raised approximately $766.8M in aggregate gross proceeds through IPO and follow-on financing by 2026-Q1, and an additional $472M in May 2026 follow-on offering. These capital raises have materially strengthened the balance sheet, supporting ongoing operations and clinical development. The trajectory shows successful capital market execution. Delivery assessment Oct 15, 2026
Maintain cash to support operations through 2029	A primary condition in VeraDermics Inc's published investment case. The stated target is Sufficient cash and equivalents to fund operations through 2029.	Intact	cash falls below level needed to support operations through 2029	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Positive trial data for hair loss drug	Trial data on a new hair loss drug could boost future sales.	Improving	trial data fails to show efficacy or safety concerns arise	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage and reduce operating losses and negative cash flow	It is working to reduce losses and improve cash flow.	Intact	operating losses and negative cash flow worsen beyond current levels	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$10,389,309	3 / 6
2026-07-25	Unavailable	$10,389,309	3 / 6
2026-07-26	Unavailable	$10,389,309	3 / 6
2026-07-27	Unavailable	$10,389,309	3 / 6
2026-07-28	Unavailable	$8,657,760	4 / 6
2026-07-29	Unavailable	$8,657,760	4 / 6
2026-07-30	Unavailable	$8,657,760	4 / 6
2026-07-31	Unavailable	$8,657,760	4 / 6
2026-08-01	Unavailable	$10,389,309	3 / 6
2026-08-02	Unavailable	$8,657,760	4 / 6
2026-08-03	Unavailable	$8,657,760	4 / 6
2026-08-04	Unavailable	$8,657,760	4 / 6
2026-08-05	Unavailable	$10,389,309	3 / 6
2026-08-06	Unavailable	$8,657,760	4 / 6
2026-08-07	Unavailable	$10,389,309	3 / 6
2026-08-08	Unavailable	$8,657,760	4 / 6
2026-08-09	Unavailable	$8,657,760	4 / 6
2026-08-10	Unavailable	$10,389,309	3 / 6
2026-08-12	Unavailable	$10,389,310	4 / 5
2026-08-13	Unavailable	$10,389,309	3 / 6
2026-08-14	Unavailable	$10,389,309	3 / 6
2026-08-15	Unavailable	$10,389,309	3 / 5
2026-08-16	Unavailable	$10,389,309	3 / 5
2026-08-17	Unavailable	$10,389,309	3 / 5
2026-08-18	Unavailable	$10,389,309	4 / 6
2026-08-19	Unavailable	$10,389,309	4 / 6
2026-08-20	Unavailable	$10,389,309	4 / 6
2026-08-21	Unavailable	$10,389,309	4 / 6
2026-08-22	Unavailable	$10,389,309	4 / 6
2026-08-23	Unavailable	$10,389,309	4 / 6
2026-08-24	Unavailable	$10,389,309	4 / 6
2026-08-25	Unavailable	$10,389,309	4 / 6
2026-08-26	Unavailable	$10,389,309	4 / 6
2026-08-27	Unavailable	$10,389,309	4 / 6
2026-08-28	Unavailable	$10,389,309	4 / 6
2026-08-29	Unavailable	$10,389,309	4 / 6
2026-08-30	Unavailable	$10,389,309	4 / 6
2026-08-31	Unavailable	$10,389,309	4 / 6
2026-09-01	Unavailable	$10,389,309	4 / 6
2026-09-02	Unavailable	$10,389,309	4 / 6
2026-09-03	Unavailable	$10,389,309	4 / 6
2026-09-04	Unavailable	$10,389,309	4 / 6
2026-09-05	Unavailable	$10,389,309	4 / 6
2026-09-06	Unavailable	$10,389,309	4 / 6
2026-09-07	Unavailable	$10,389,309	4 / 6
2026-09-08	Unavailable	$10,389,309	4 / 6
2026-09-09	Unavailable	$10,389,309	4 / 6
2026-09-10	Unavailable	$10,389,309	4 / 6
2026-09-11	Unavailable	$10,389,309	4 / 6
2026-09-12	Unavailable	$10,389,309	4 / 6
2026-09-13	Unavailable	$10,389,309	4 / 6
2026-09-14	Unavailable	$10,389,309	4 / 6
2026-09-15	Unavailable	$10,389,309	4 / 6
2026-09-16	Unavailable	$10,389,309	4 / 6
2026-09-17	Unavailable	$10,389,309	4 / 6
2026-09-18	Unavailable	$10,389,309	4 / 6
2026-09-19	Unavailable	$10,389,309	4 / 6
2026-09-20	Unavailable	$10,389,309	4 / 6
2026-09-21	Unavailable	$10,389,309	4 / 6
2026-09-22	Unavailable	$10,389,309	4 / 6
2026-09-23	Unavailable	$10,389,309	4 / 6
2026-09-24	Unavailable	$10,389,309	4 / 6
2026-09-25	Unavailable	$10,389,309	4 / 6
2026-09-26	Unavailable	$10,389,309	4 / 6
2026-09-27	Unavailable	$10,389,309	4 / 6
2026-09-28	Unavailable	$10,389,309	4 / 6
2026-09-29	Unavailable	$10,389,309	4 / 6
2026-09-30	Unavailable	$10,389,309	4 / 6
2026-10-01	Unavailable	$10,389,309	4 / 6
2026-10-02	Unavailable	$10,389,309	4 / 6
2026-10-03	Unavailable	$10,389,309	4 / 6
2026-10-04	Unavailable	$10,389,309	4 / 6
2026-10-05	Unavailable	$10,389,309	4 / 6
2026-10-06	Unavailable	$10,389,309	4 / 6
2026-10-07	Unavailable	$10,389,309	4 / 6
2026-10-08	Unavailable	$10,389,309	4 / 6
2026-10-09	Unavailable	$10,389,309	4 / 6
2026-10-10	Unavailable	$10,389,309	4 / 6
2026-10-11	Unavailable	$10,389,309	4 / 6
2026-10-12	Unavailable	$10,389,309	4 / 6
2026-10-13	Unavailable	$10,389,309	4 / 6
2026-10-14	Unavailable	$10,389,309	4 / 6
2026-10-15	Unavailable	$10,389,309	4 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	0	0
2026-06-01	6	0	0
2026-07-01	7	0	0
2026-08-01	7	0	0
2026-09-01	7	0	0
2026-10-01	7	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 16–Oct 15 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Complete capital raise via public offeringDirect metric needs a verified mapping
Maintain cash to support operations through 2029Direct metric needs a verified mapping
Positive trial data for hair loss drugDirect metric needs a verified mapping
Manage and reduce operating losses and negative cash flowDirect metric needs a verified mapping

Next proof point

Nov 10, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-24.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

VeraDermics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a turnaround scenario. The current thesis state is cautious, as recent financial performance has been weak, and the company is navigating operating losses while focusing on R&D investment.

What's priced into VeraDermics Inc

The market currently assumes a low level of fragility, as no significant negative events have triggered a change in sentiment. However, there is an expectation that the company needs to improve its financial performance to align better with its industry peers.

What the fundamentals likely do

Management is on track with their priorities, including advancing clinical development and maintaining a strong capital position. However, the company's recent financial performance has been weak, and there is a moderate risk of missing future earnings expectations.

What VeraDermics Inc hinges on

The thesis hinges on several factors, including whether management will cut guidance, the impact of a weakening jobs report on the healthcare sector, and the performance of sector bellwethers like VRTX, MRNA, and REGN.